Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2014-02-21 Earnings Release
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Presentation of the fourth quarter and full year 2013 report
Earnings Release Classification · 95% confidence The document explicitly announces the 'Presentation of the fourth quarter and full year 2013 report' and provides details about the time, location, and participants for this presentation, including a webcast/conference call. This structure—announcing an upcoming event where financial results will be discussed—is characteristic of an Earnings Release (ER) or, more specifically, an announcement related to the presentation of results. Since it details the event where the results are presented rather than being the full transcript (CT) or the initial highlights (ER), and given the context of presenting annual/quarterly results, it aligns best with an announcement preceding the main event. However, the definitions provided suggest ER is for initial highlights. Since this document is purely an announcement of *when and where* the presentation of the Q4/FY report will occur, it fits the description of a Report Publication Announcement (RPA) as it announces the publication/presentation of the underlying report, or potentially a Regulatory Filing (RNS) if it's a mandatory disclosure about the event itself. Given the specific nature of announcing the presentation event details, RPA is a strong candidate, but since it is announcing the presentation of the *results*, and the document is short and focuses on the logistics of the presentation, it is most accurately classified as an announcement about the release of information. If the content were the presentation slides themselves, it would be IP. Since it is the announcement of the presentation event for the Q4/FY report, and it is short, RPA (Report Publication Announcement) is the most fitting category for announcing the logistics of the report's release/presentation. FY 2013
2014-02-21 English
Flaggemelding
Director's Dealing Classification · 98% confidence The document text is very short (253 characters) and describes a transaction involving the sale of shares by an insider (Gezina AS, likely a director or major shareholder, given the context of such filings). The content explicitly states the number of shares sold, the price, and the resulting new holding percentage (4.5%). This strongly indicates a notification of a director's or executive's personal share transaction, which corresponds to the 'Director's Dealing' category (DIRS). Although the title is 'Flaggemelding' (Flagging announcement, common in Nordic markets for insider/major shareholder transactions), the content matches DIRS better than MRQ (Major Shareholding Notification), as it details a specific transaction rather than just crossing a threshold.
2014-01-29 Norwegian
Photocure ASA - Notification of trade
Transaction in Own Shares Classification · 100% confidence The document explicitly details a share buyback transaction, stating that Photocure ASA purchased 5,000 of its own shares on February 7, 2011. This falls directly under the definition of 'Transaction in Own Shares' (POS).
2011-02-07 English
Photocure ASA - Kjøp av egne aksjer
Transaction in Own Shares Classification · 100% confidence The document is a short announcement detailing the purchase of the company's own shares (share buyback) by Photocure ASA. It specifies the number of shares purchased (5,000), the average price (53.89 NOK), and the total holdings after the transaction. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2011-02-07 Norwegian
Photocure ASA - Positive Allumera Trial Results
Regulatory Filings Classification · 95% confidence The document is a press release announcing the positive results of a clinical trial for a product called Allumera. It details the study methodology, statistical outcomes, and quotes from company leadership. It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations and product development, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate disclosures.
2011-02-04 English
Photocure ASA - Positive resultater fra Allumera studie
Regulatory Filings Classification · 95% confidence The document is a press release from Photocure ASA announcing positive clinical trial results for their product 'Allumera'. It provides details on the study methodology, statistical results, and quotes from management. It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement (RPA) as it contains the actual findings rather than just a notice of a report's availability. As it is a general corporate announcement regarding business operations and product development, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for such corporate disclosures.
2011-02-04 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.